Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window FDA staff raised ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Sotagliflozin was linked to lower HbA1c for users with ...

Time to clinical benefit was assessed. The x-axis represents time from randomization, and the y-axis represents the degree of benefit at that time, as measured by the hazard ratio shown in blue. The ...

Houston, TX (November 7, 2025) — Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney ...

THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug ...